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Abstract
Exosomes are cellular secretory vesicles containing microRNAs (miRNAs). Once secreted, exosomes are able to attach to
recipient cells and release miRNAs potentially modulating the function of the recipient cell. We hypothesized that exosomal
miRNA expression in brains of patients diagnosed with schizophrenia (SZ) and bipolar disorder (BD) might differ from
controls, reflecting either disease-specific or common aberrations in SZ and BD patients. The sources of the analyzed
samples included McLean 66 Cohort Collection (Harvard Brain Tissue Resource Center), BrainNet Europe II (BNE, a
consortium of 18 brain banks across Europe) and Boston Medical Center (BMC). Exosomal miRNAs from frozen postmortem
prefrontal cortices with well-preserved RNA were isolated and submitted to profiling by Luminex FLEXMAP 3D microfluidic
device. Multiple statistical analyses of microarray data suggested that certain exosomal miRNAs were differentially
expressed in SZ and BD subjects in comparison to controls. RT-PCR validation confirmed that two miRNAs, miR-497 in SZ
samples and miR-29c in BD samples, have significantly increased expression when compared to control samples. These
results warrant future studies to evaluate the potential of exosome-derived miRNAs to serve as biomarkers of SZ and BD.
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Introduction
Knowing which molecules are specifically altered in neuropsy-
chiatric patients would represent a crucial step towards uncovering
mechanisms of the development of neuropshychiatric diseases and
generating more successful therapeutic strategies. An immediate
impact of identifying such molecules would be access to a set of
biomarkers to help define and monitor populations at risk.
MicroRNAs (miRNAs, miRs) may up- or down-regulate the
translation of messenger RNA (mRNA) or render it unstable, and
have recently been proposed as biomarkers for brain neoplasms,
degenerative diseases, autism, and schizophrenia [1]. Dysregula-
tion of miRNAs in brains of patients diagnosed with schizophrenia
(SZ) [2] and other neuropsychiatric disorders is plausible
considering that many miRNAs are expressed in human brain
[3] where they regulate neuronal development [4] and differen-
tiation [5] including dendritic spine development [6] and plasticity
[7],[8], as well as cognitive functions [9]. A group of miRNAs has
been recently designated as ‘‘misexpressed’’ in the prefrontal
cortices (PFCs) of both SZ and bipolar disorder (BD) patients [10].
The target analysis of another reported set of differentially
expressed miRNAs in the PFCs of SZ patients revealed many
genes implicated in signaling pathways [11]. While a specific BD
miRNA profile has not yet been established, alterations in
neurochemical regulation including an excess in signaling activity
have been associated with BD [12].
Signaling activity in neurons commonly requires the release of
signaling molecules from their specific secretory vesicles [13].
Exosomes are secretory vesicles defined by size (30–90 nm),
buoyant density (,1.1–1.2 g/ml), lipid composition, and the
presence as well as the absence of specific marker proteins [14].
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Exosomes represent the alternative route for the content of
multivesicular bodies (MVBs, exosomal precursor organelles)
destined for degradation in lyzosomes. Rather then being
degraded, MVBs’ intraluminal vesicles are fused with the plasma
membrane and secreted into the extracellular space as exosomes
[15]. Because of the specific molecules on their surface, including
cell-adhesion proteins, exosomes can be incorporated by specific
recipient cells [15],[16]. The exosomal involvement in neuronal
signaling was suggested by the presence of MVBs in dendritic
spines [17],[18] and by the resemblance of synaptic spinules
(evaginations of the postsynaptic membrane that bud into
presynaptic axon) to exosomes [19],[20]. The role of exosomes
in synaptic activity is further corroborated by the dependence of
long term potentiation (LTP)-induced structural spine plasticity on
exocytic trafficking from recycling endosomes [21].
Cultured primary cortical neurons and astrocytes do release
exosomes [22]. Studies of exosomal cargo in neurons and
microglia have revealed proteins important for the development
of neurodegenerative diseases such as Alzheimer’s disease [23–26]
and Parkinson’s disease [27]. Exosomes in neuronal cell lines have
also been shown to transfer prions [28] as well as wild-type and
mutant superoxide dismutase, thus propagating cell-to-cell mutant
toxicity [29]. Microarray analysis of exosomal content from mouse
bone marrow mast cells and human and mouse mast cell lines has
established the presence of mRNA and miRNA [30]. A new name
for this mRNA - ‘‘exosomal shuttle RNA’’ [30] - has been
proposed to underscore the ability of exosomes to mediate the
exchange of genetic material between cells. Changes in exosomal
miRNAs have been reported in patients diagnosed with Alzhei-
mer’s disease [31], while RNA content from the glioblastoma
microvesicles was shown to provide diagnostic biomarkers [32].
Postmortem human PFC samples have been used to successfully
generate miRNA profiles [11]. Here we report the results of
exosomal miRNA expression analysis in PFCs from patients
diagnosed with SZ, BD, and mental illness-free controls. We have
observed aberrations in SZ and BD samples in comparison to
controls, suggesting both common and differential pathobiology.
These results may forecast reproducible, disease-associated
changes of miRNA expression serving as biomarkers in exosomes,
cellular particles potentially obtainable from the cerebrospinal
fluid (CSF) of living patients.
Materials and Methods
Human Brain Tissue
Written informed consent was obtained from the next of kin for
the use of the postmortem brain tissue by the following sources of
frozen PFC (Brodmann area 9, BA9): BrainNet Europe II, a
consortium of 18 brain banks across Europe (BNE; cases SZ 1–6,
BD 5–9, and C 6–10), McLean 66 Cohort Collection at Harvard
Brain Tissue Resource Center (McLean; cases SZ 7 and 8, BD 1–
4, and C 1–5), and autopsy service at Boston Medical Center
(BMC; cases C 11–13) (Table 1).
Extractions of Exosome-containing Pellets
Exosome extraction protocol from primary and cultured cells
[30] was modified to obtain exosome-containing pellets from
frozen brain tissue that was previously evaluated for RNA integrity
(Figure S1). Only the brain tissue samples yielding an RNA
integrity number (RIN) of $5.1 (range 5.1–9.1, Table 1) and thus
well within accepted standards [33] were used to obtain exosome-
containing pellets. From the original frozen prefrontal cortex
stored at 280uC procured by each brain bank, we cut
approximately 600 mg of grey matter using a razor blade. The
frozen tissue was put in 1 ml phosphate-buffered saline, pH 7.4
(PBS, 4uC), gently teased with a small spatula, and vortexed (VWR
mini-vortexer) on a medium power. Each tube was centrifuged at
3006g for 10 min, decanted, centrifuged twice at 1,2006g for
10 min with decanting in between, and finally filtered through a
0.2 um syringe filter (Millipore, Carrigtowhill, Cork, Ireland). The
filtrate was centrifuged twice at 10,0006g for 30 min with
decanting in between. The final centrifugation to obtain exo-
some-containing pellets was performed at 22,0006g for 22 hrs. All
centrifugations were performed at 2uC.
As a control exosomal extraction procedure, exosomes from
cultured human H4 cells (HTB 148 ATCC, Manassas, VA, USA)
were prepared as previously published [16–34] with minor
modifications. Briefly, H4 cells were cultured in OPTIMEM
medium (Life Technologies) without serum or antibiotics. After 48
hours, conditioned medium was collected and centrifuged for
5 min at 5006g at 4uC to remove cell debris. The supernatants
were then sequentially centrifuged at 3006g (10 min) and twice at
2,0006g (10 min), 4uC. The supernatant was filtered through a
0.45 um (Whatman, Florham Park, NJ) and 0.22 um (Millipore,
Carrigtowhill, Cork, Ireland) filter, and centrifuged for 1 hr at
10,0006g at 4uC. The supernatant was removed and then
subjected to ultracentrifugation at 100,0006g for 2 hours at
4uC. The supernatant was collected and the exosome-containing
pellet was re-suspended in PBS for Western Blotting.
Transmission Electron Microscopy (TEM) and Immuno-
gold Labeling
For morphological identification of exosomes, the pellets were
either embedded in a hydrophilic resin upon fixation in TEM
fixative (4% paraformaldehyde, 0.2% glutaraldehyde, in 0.2 M
cacodylate buffer, pH 7.2.) or directly adsorbed to a carbon-
coated grid that has been made hydrophilic by an exposure to a
glow discharge (30 sec). Upon blocking with 1% Bovine Serum
Albumin (BSA), grids with pellets were incubated in primary
antibody (CD63, BD Pharmingen, and GAPDH, Ambion) solutions in
1% BSA, rinsed in PBS, exposed to either bridging antibody first
or directly to protein A-gold (5 nM) solution in 1% BSA, rinsed in
PBS, and finally in water. Excess liquid was removed with a filter-
paper (Whatman #1). Optional negative staining was achieved by
incubation in 0.75% uranyl formate for 30 seconds. The
examination was carried out in a JEOL 1200EX TEM or a
TecnaiG2 Spirit BioTWIN and images were recorded with an
AMT 2k CCD camera.
Western Blotting
The expression of an exosomal marker flotillin-2 [35] in the
exosomal preparations from frozen postmortem PFC was com-
pared to the flotillin-2 expression in the cell-culture-derived
exosomal preparations described above. Equal protein amounts
(2.5 mg/ml) from each exosome-containing pellet reconstituted in
PBS and respective supernatant were blotted with anti-flotillin-2
antibody (BD Transduction Laboratories, 1:1,000).
Isolation, Purification, and Linear Amplification of miRNA
from Exosome-containing Pellets
Exosome-containing pellets re-suspended in 20 ul of PBS were
incubated with 0.4 mg/ml of RNase A/T1 (Fementas) for 10 min at
37uC. RNase was inactivated by adding 20 units/ul of SuperRase-in
RNase inhibitor (Ambion) for 10 min at 25uC. The RNase
treatment destroyed the higher molecular weight extra-exosomal
cellular RNAs and preserved the small RNAs contained in the
exosomes, i.e. ribosomal RNA and miRNA (Figure S2). Upon
miRNAs in Schizophrenia and Bipolar Disorder
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RNase inactivation, 60 ul of miRNA extraction buffer (Arcturus)
was added, followed by an incubation at 42uC for 30 min and
purification using PicoPure RNA Isolation Kit (Lifetech). The
expected size range of miRNAs (,19–28 nucleotides, nt) and
pre-miRNAs (45–60 nt) were well-represented in the purified
preparations (Figure S2). Because Luminex profiling system
operates with inputs of 2.5–5 ug of total RNA per sample, we
needed to ensure that our samples are sufficiently enriched for
miRNA. To that end, we used Invitrogen NCode miRNA amplifi-
cation system according to the manufacturer’s protocol to linearly
amplify miRNA in our material (Table S2). We found that this
amplification step upon above described RNA treatment did not
induce changes in the RNA profile (Figure S3).
Table 1. Analyzed human prefrontal cortices (BA9).
Case and
Disease Age
Gender/
Hemisphere PMI
Neuropathology and pertinent
clinical history Source RIN Experiment
SZ1 74 M/left 6 BB II, alpha-synuclein immunoreactivity
in few SN neurons
BNE 8.3 L, P
SZ2 65 M/left 3.5 BB I, lacunar infarct in the caudate BNE 8.3 L, P
SZ3 82 M/left 4.5 BB VI, amyloid angiopathy, lacunar
infarct in putamen
BNE 9.1 L, P
SZ4 77 M/left 6 BB II, old infarct in the frontal lobe BNE 8.3 L, P
SZ5 84 M/left 2.5 BB II, amyloid angiopathy, argirofilic
grain disease
BNE 8.3 L, P
SZ6 79 M/left 2.5 multiple infarcts in the teritories of middle
and posterior cerebral artery circulation
BNE 7.8 L, P
SZ7 63 M/right 22.3 BB I McLean 7.6 L
SZ8 35 M/left 28 BB I, non-specific fronto-temporo-parietal
and thalamic atrophy
McLean 6.1 L
BD1 40 M/left 30.8 acute hypoxic changes, focal
arteriolosclerosis
McLean 6.7 L
BD2 38 M/left 22 parietal cortex infarct, focal acute hypoxic
changes, focal arteriolosclerosis
McLean 7.9 L
BD3 50 M/right 30.5 no neuropathology reported McLean 7.1 L
BD4 74 M/right 25 no neuropathology reported McLean 6.6 L
BD5 73 M/right 5.3 BB II, temporal SPs, small old cortical
and striatal infarcts
BNE 6.2 L, P
BD6 70 M/left 6.4 BB III, many SP, few NP, contusions (due
to fall); alcohol abuse
BNE 6.2 L, P
BD7 68 M/left NA BB I BNE 5.5 P
BD8 93 M/left 6 BB I BNE 5.1 P
BD9 90 F/left 6.5 BB I-II, rare SP BNE 7.7 P
C1 67 M/right 22.3 BB I, lacunar infarcts in putamen, focal
arteriolosclerosis
McLean 8.0 L
C2 37 M/right 18.7 minimal acute hypoxic-ischemic change
in hippocampus
McLean 6.4 L
C3 38 M/left 28.8 no neuropathology reported McLean 7.7 L
C4 50 M/left 24.1 BB I McLean 6.2 L
C5 40 M/right 28 no neuropathology reported McLean 7.1 L
C6 68 M/left 10.2 no neuropathology reported BNE 6.4 L, P
C7 71 M/left 7.6 BB I, lacunar infarct in internal capsule BNE 6.1 P
C8 82 F/left 7 severe atherosclerosis in the circle of
Willis, focal gliosis in striatum
BNE 6.1 P
C9 96 M/right 5.4 BB I, rare SP, rare NP, hypoxic-ischemic
changes in striatum and hippocampus
BNE 6.0 P
C10 65 F/left 12.8 no neuropathology BNE 8.1 P
C11 80 M/left 17 no neuropathology BMC 5.9 P
C12 72 F/left 23 no neuropathology BMC 5.1 P
C13 68 F/left 25 no neuropathology BMC 7.0 P
SZ = schizophrenia; BD= bipolar disorder; C = controls.
BB = Braak and Braak.
L = Luminex; P = qPCR.
doi:10.1371/journal.pone.0048814.t001
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Luminex miRNA Assay
We performed miRNA expression analysis using a FlexMAP3D
instrument by (Luminex Corporation, Austin, TX) and a
manufacturer’s assay for 312 miRNA (Table S1). This assay uses
5.6 um polystyrene micro-beads each of which contains a mixture
of two fluorescent dyes that enable the beads to be identified as
one of a specific set. Oligonucleotides, specific for each of our 312
miRNA assayed, were attached to the beads according to the
manufacturer’s protocol. The beads, upon incubation with
miRNA containing samples, were passed through a fluidic tube
that causes the micro-spheres to line up in single file before they
pass through the detection chamber that contains two lasers. One
of the laser beams classifies each bead into the appropriate bead
set, while the other scans the beads for the presence of fluorescent
reporter molecules and quantifies the number of reporter
molecules on each bead. All 312 miRNA were assayed simulta-
neously in each sample. Intra-normalization of the obtained
expression values was performed according to the Luminex
protocol. Negative values were considered ‘‘0’’ because they
indicate the expression below the background, i.e. the absence of a
specific miRNA signal (Table S1).
Statistical Analysis of Luminex miRNA Expression Data
Student’s t-tests and statistical software packages including an
Excel plug-in named Significance Analysis of Microarrays (SAM)
[36],[37] and an R package named Prediction Analysis of
Microarrays (PAM) [38] were used to analyze Luminex expression
data on 312 miRNAs from the prefrontal cortex of 8 SZ, 6 BD,
and 6 control samples (Table 1 and Table S1). Because the
statistical analysis of these data involves multiple comparisons we
applied Bonferroni Step-down Holm Correction [39] to Student’s
t-test outcomes [0.05/(312–number of miRNAs ranked higher)],
resulting in a stricter threshold for significance (Table S1). Next,
we used SAM and PAM because they provide multiclass testing
[36–38] while a simple t-test only enables analysis between two
groups. Multiclass testing was a necessary tool to identify a set of
miRNAs that could be used to differentiate between all three
groups. Both SAM and PAM use a modified z-score statistic [36–
38] to produce a ranked list of candidate biomarker miRNAs. The
adjustment for codependency of expression was performed as local
False Discovery Rate (FDR) [37], [40] presented in Tables 2 and
3. FDR is a method of permutation testing [41] that evaluates the
risk of Type 1 error. Local FDR is an FDR assessment of not only
a single miRNA, but also its ‘‘neighbors’’, i.e. other closely ranked
miRNAs. In this way, a co-dependency is accounted for. Cluster
analysis [38] was applied to those miRNAs that had ‘‘00 q-values
in SAM (Tables 2 and 3). Clustering was carried out through use
of 2*(1-cc) where cc equals a correlation between the cubed root of
a single miRNA expression value for a sample and the average of
cube-rooted values for all samples in the cluster it joins at that time
point. The highest possible correlation between samples is 1 and
the lowest is 0, resulting in a dendrogram that presents the
clustered samples on a scale of 0 to 2. The dendrogram begins
clustering miRNA with most similar expression patterns at the
bottom of the graph and then additional miRNA are added to
existing clusters as the graph is assembled vertically. In order to
assess the predictive power of SAM-ranked miRNAs, the
misclassification rate [38–42] was established as a means to
classify clinical groups. A low misclassification rate indicates that a
miRNA or a set of miRNAs is a reliable predictor of a group
phenotype (a biomarker). Because of the limited number of cases
available for analysis, we performed Wilcoxon test to supplement
our findings (Table S3).
Table 2. SAM test of Luminex miRNA expression data for all 3
examined groups of cases: SZ, BD, and C.
miRNA
z-score:
C
z-score:
BD
z-score:
SZ q-value(%) local FDR(%)
hsa-miR-31 22.1970922.54002 3.55283 0 1.553882119
hsa-miR-33 22.1763721.95758 3.10046 0 2.433615922
hsa-miR-96 21.9936321.9829 2.9824 0 2.493468788
hsa-miR-28 21.4072321.68092 2.31611 0 2.300536436
hsa-miR-30e-5p 21.0135322.15639 2.37744 0 2.438595672
hsa-miR-199a* 21.5206421.43723 2.21841 0 2.580013124
hsa-miR-501 2.162398 20.31372 21.38651 0 2.585758655
hsa-miR-504 1.9952 20.30377 21.26857 0 2.662187029
hsa-miR-15b 20.8329421.75496 1.94092 0 2.659473233
hsa-miR-29c 2.068676 20.39402 21.25599 0 2.649467758
hsa-miR-455 21.4940521.08385 1.93342 0 2.611617439
hsa-miR-380-3p 1.878938 20.83204 20.78517 0 2.621226767
hsa-miR-323 21.3998220.99834 1.79862 0 2.626487216
hsa-miR-527 1.535186 0.010721 21.15943 0 2.807651873
hsa-miR-93 21.3170620.81606 1.59984 0 2.851798957
hsa-miR-32 21.0136521.26054 1.70564 0 2.86415899
hsa-miR-20b 21.2486521.25458 1.87742 0 2.873400151
hsa-miR-516-5p 1.441361 20.31318 20.84614 0 2.997241768
hsa-miR-92 21.1210820.96419 1.56396 0 3.013501643
hsa-miR-30a-3p 21.1898321.04924 1.67931 0 3.063908167
hsa-miR-497 1.63309 20.87672 20.56728 0 3.16010056
hsa-miR-498 1.256994 20.11349 20.85762 2.17948718 4.322678597
hsa-miR-133b 21.3412820.7324 1.55526 2.17948718 4.639798252
hsa-miR-499 1.736963 20.88259 20.64078 2.17948718 4.738725328
hsa-miR-10b 20.7221321.17673 1.42415 2.17948718 4.878212949
hsa-miR-202* 20.9101 21.73414 1.98318 2.17948718 4.898293562
hsa-miR-202 20.14303 1.238359 20.82149 2.17948718 5.065305767
hsa-miR-149 1.490285 20.74638 20.55793 2.17948718 7.055913859
hsa-miR-523 0.88386 0.910065 21.34544 2.17948718 7.62760309
hsa-miR-199b 20.8725420.91723 1.34233 2.17948718 7.857837003
hsa-miR-377 20.9798721.24239 1.6667 3.73626374 9.314491623
hsa-miR-518b 0.322664 0.980094 20.97707 3.73626374 9.367786992
hsa-miR-26b 1.336505 20.36918 20.72549 3.73626374 9.819393964
hsa-miR-190 21.4423221.32539 2.07578 3.73626374 10.24724163
hsa-miR-326 20.1038 1.199379 20.82169 3.73626374 10.34765218
hsa-miR-494 0.293894 0.910858 20.90356 3.73626374 11.67285654
hsa-miR-30e-3p 1.314221 20.87488 20.32951 3.73626374 12.18718064
hsa-miR-512-3p 20.17555 1.286875 20.83349 3.73626374 12.89683212
hsa-miR-302a* 20.4763821.30373 1.33509 3.73626374 13.04097715
hsa-miR-19b 20.28889 1.482134 20.89494 3.73626374 13.11908036
hsa-miR-302c 20.12265 1.445789 20.99236 4.84330484 14.25507383
hsa-miR-218 0.521858 1.207283 21.29686 4.84330484 14.36727552
hsa-miR-338 21.3316720.78432 1.58699 4.84330484 14.76902994
hsa-miR-423 0.477963 0.812936 20.96817 4.84330484 14.83356578
hsa-miR-200c 21.3661521.22514 1.94347 4.84330484 15.64595147
hsa-miR-325 0.109128 1.083419 20.89441 4.84330484 15.97503816
hsa-miR-376b 1.029142 20.00167 20.7706 4.84330484 16.33334873
hsa-miR-518c 21.3448920.8751 1.66499 4.84330484 17.02063785
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Table 2. Cont.
miRNA
z-score:
C
z-score:
BD
z-score:
SZ q-value(%)local FDR(%)
hsa-miR-525* 20.9387821.06791 1.50502 4.84330484 17.14036115
hsa-miR-125b 20.8601320.85856 1.28902 4.84330484 17.17411684
hsa-miR-299-3p 1.138288 20.02057 20.83829 4.84330484 18.19059244
hsa-miR-363* 0.02007 0.987996 20.75605 4.84330484 18.33451874
hsa-miR-542-3p 0.990978 0.007651 20.74897 4.84330484 18.33773541
hsa-miR-371 0.798332 0.593946 21.04421 4.84330484 18.36737645
hsa-miR-105 1.116132 0.542534 21.244 7.00549451 22.95334699
hsa-miR-449 0.914034 0.511142 21.06888 7.00549451 23.04808523
hsa-miR-370 1.088913 20.34469 20.55817 8.02968961 25.80170896
hsa-miR-302d 20.8247121.17696 1.50126 8.02968961 27.03187735
hsa-miR-22 21.0177721.05168 1.55209 8.02968961 27.64688383
hsa-miR-17-5p 0.337338 0.922478 20.94486 8.02968961 27.75618225
hsa-miR-518a-2* 1.201014 20.2914 20.68221 8.02968961 28.15873897
hsa-miR-103 20.4895320.73475 0.91821 8.02968961 28.42825986
hsa-miR-520d* 1.460088 20.4613 20.74909 9.90675991 29.0140902
hsa-miR-18a* 20.8946220.66084 1.1666 9.90675991 30.34475207
hsa-miR-210 20.05258 1.249962 20.89804 9.90675991 31.08028153
hsa-miR-520e 20.4763321.04849 1.14362 9.90675991 31.70287333
hsa-miR-516-3p 1.187797 0.108884 20.97251 9.90675991 32.5639352
hsa-miR-329 20.9053 1.414948 20.38224 9.90675991 33.43751026
hsa-miR-182 21.0740820.71552 1.3422 9.90675991 33.54506373
hsa-miR-380-5p 0.31583 0.983345 20.97438 9.90675991 34.0190772
hsa-miR-30c 21.18267 0.402311 0.58527 9.90675991 35.0288034
hsa-miR-106b 20.08408 1.027975 20.70792 11.587147 35.57300849
hsa-miR-219 1.517496 20.96688 20.41296 11.587147 35.95711034
hsa-miR-16 20.9206820.50831 1.07174 11.587147 36.48103455
hsa-miR-490 0.150144 0.835278 20.73907 11.587147 37.01897704
hsa-miR-367 0.797077 0.41705 20.9106 11.587147 37.31177035
hsa-miR-320 20.25449 0.937805 20.51249 11.587147 37.998358
hsa-miR-135b 0.337006 0.857104 20.89558 11.587147 38.84789583
hsa-miR-206 20.3697 0.94394 20.43068 11.587147 39.10460163
hsa-miR-526b* 1.208306 20.78313 20.31888 11.587147 40.34787385
hsa-miR-425 20.85102 1.009775 20.11907 11.587147 40.77866903
hsa-miR-376a 0.920047 20.1274 20.59448 11.587147 40.92694087
hsa-miR-503 0.888295 20.13607 20.56417 14.1171329 42.85245703
hsa-miR-487a 0.162841 0.82095 20.73784 14.1171329 43.30927731
hsa-miR-106a 0.521766 0.595635 20.83805 14.1171329 43.48858371
hsa-miR-100 0.056388 21.20747 0.86331 14.1171329 44.10398892
hsa-let-7f 20.9343920.05581 0.74264 14.1171329 44.67888809
hsa-miR-511 0.310344 21.0703 0.56996 14.1171329 44.90173075
hsa-miR-544 1.131482 20.56382 20.42574 14.1171329 47.12197196
hsa-miR-487b 20.8211220.41659 0.92829 14.1171329 47.26591312
hsa-miR-363 21.2717820.56825 1.38003 14.1171329 47.48233294
hsa-miR-376a* 0.390564 0.732719 20.84246 14.1171329 48.56245152
hsa-miR-375 0.243853 0.644572 20.66632 16.5048544 49.01224431
hsa-miR-153 20.9969 21.14696 1.60789 16.5048544 49.40211523
hsa-miR-431 20.8210620.91197 1.29978 16.5048544 49.44548869
hsa-miR-217 20.9901620.31608 0.97968 16.5048544 49.52370084
hsa-miR-362 20.2857321.02521 0.98321 16.5048544 49.87006572
Table 2. Cont.
miRNA
z-score:
C
z-score:
BD
z-score:
SZ q-value(%) local FDR(%)
hsa-miR-500 0.980354 20.56183 20.31389 16.5048544 50.74516842
hsa-miR-372 20.9645820.95534 1.43994 16.5048544 50.99446275
hsa-miR-148a 0.828874 21.04752 0.16398 16.5048544 51.40114981
hsa-miR-10a 20.6404720.52695 0.87556 16.5048544 52.40792839
hsa-miR-433 20.22833 0.946138 20.53835 16.5048544 52.46791499
hsa-miR-29b 0.620123 21.14248 0.39177 16.5048544 52.72930619
hsa-miR-382 20.23578 0.894415 20.49398 16.5048544 53.59705171
hsa-miR-335 20.3399 0.856229 20.38725 16.5048544 53.75101383
hsa-miR-381 20.8172420.5501 1.02551 16.5048544 54.38769193
hsa-miR-513 0.767999 0.015731 20.5878 18.2605683 54.93952212
hsa-miR-328 0.233808 0.700291 20.70057 18.2605683 55.70006535
hsa-miR-518e 20.7383320.62201 1.02026 18.2605683 56.00690632
hsa-miR-301 0.120635 0.905541 20.76963 18.2605683 56.02980543
hsa-miR-25 20.6663920.6356 0.97649 18.2605683 56.32551846
hsa-miR-518d 0.155299 0.838491 20.74534 19.8489011 58.23570838
hsa-miR-342 0.551634 21.20248 0.48813 22.5464191 59.93768974
hsa-miR-521 20.9650620.45523 1.06522 22.5464191 60.4907877
hsa-miR-520a 0.84235 21.11148 0.20185 22.5464191 60.95727772
hsa-miR-409-5p 0.882507 20.76108 20.09107 22.5464191 61.30748083
hsa-miR-485-3p 0.386518 0.492904 20.65957 24.0302433 62.62241634
hsa-miR-200a 0.092787 20.91805 0.61894 25.0641026 63.41566145
hsa-miR-29a 0.482776 0.519518 20.75172 25.0641026 63.78211013
hsa-miR-429 0.055713 0.792367 20.63606 25.0641026 63.82820222
hsa-miR-125a 0.805608 20.59199 20.16021 28.4739454 65.48468447
hsa-miR-502 0.754098 20.67512 20.05923 28.4739454 65.82932368
hsa-miR-17-3p 20.4352220.7476 0.88711 28.4739454 66.19614625
hsa-miR-148b 0.174623 20.94181 0.57539 28.4739454 66.43951644
hsa-miR-368 0.743991 20.88733 0.10751 28.4739454 67.12123684
hsa-miR-142-3p 20.2051621.124 0.99687 31.1598558 67.73036369
hsa-miR-205 0.249306 0.845495 20.8211 31.1598558 67.86858747
hsa-miR-373* 0.052207 0.60096 20.48988 31.1598558 68.0705944
hsa-miR-517* 20.6338320.14053 0.58077 32.4408284 68.51734889
hsa-miR-186 20.35485 0.80983 20.34124 32.4408284 68.75244349
hsa-miR-452* 20.2791620.91071 0.8924 32.4408284 70.00183058
hsa-miR-181d 0.830156 20.52455 20.2292 32.4408284 70.12549652
hsa-miR-489 20.5622520.14396 0.52966 32.4408284 70.13050269
hsa-miR-183 0.159174 0.686645 20.63436 32.4408284 70.19307622
hsa-miR-30d 20.43691 0.770014 20.24983 32.4408284 70.23265424
hsa-miR-483 0.815477 20.84234 0.02015 32.4408284 70.60907344
hsa-let-7a 20.70813 0.463107 0.18377 32.4408284 70.71775515
hsa-miR-451 21.23771 0.247949 0.74232 32.4408284 70.91507517
hsa-miR-221 20.8755620.58425 1.09486 32.4408284 71.4883905
hsa-miR-507 20.3519720.58369 0.70175 32.4408284 71.49526037
hsa-miR-526b 0.030514 0.581534 20.45904 32.4408284 71.53582005
hsa-miR-496 0.850841 20.05299 20.59839 32.4408284 71.54645244
hsa-miR-185 0.031791 0.573309 20.45383 32.4408284 71.56623333
hsa-miR-510 0.742406 20.56788 20.13089 32.4408284 71.60493642
hsa-miR-452 0.02098 0.573449 20.44582 32.4408284 71.81598617
hsa-miR-127 20.7052920.18458 0.6674 32.4408284 71.9211001
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qPCR Analysis
Upon isolation and purification of RNA from exosome-
containing pellets as above, the RNA concentration of each
sample tested (Table 1) was calculated using Agilent Bioanlyzer 2100
data. 20 ng of RNA was used to synthesize cDNA in a 20 ul
reaction volume employing Exiqon mIRCURY LNA microRNA
PCR Universal cDNA Synthesis Kit (Denmark). Quantitative
PCR (qPCR) reactions for miRNAs of interest were performed
according to the same manufacturer’s protocol. Briefly, cDNA was
diluted to a final concentration of 0.1 ng/ul, added to a primer set
generated by Exiqon and PCR SYBR Green Master Mix by the
same manufacturer, and run for 40 cycles on a Bio-Rad iCycler. To
obtain a change in CT (Delta-CT) for each miRNA of interest we
needed to have an internal control in every sample. Luminex data as
well as preliminary qPCRs established that miR-423 had a stable
and robust expression in the samples tested (Table S1). Thus, all
the analyzed samples were run in duplicates for each miRNA of
interest and for miR-423 as a reference [43–45], (http://www.
exiqon.com/ls/Documents/Scientific/miRNA-qPCR-guidelines.
pdf) in a minimum of three separate plates. In each plate, the
average CT value for miR-423 was subtracted from average CT
value for a given miRNA of interest to obtain a value of change in
CT (Delta-CT) for every sample. Student’s t-tests on control and
BD and on control and SZ Delta-CT values were performed using
Graph Pad Prism 5.
Results
Exosomal Marker Identification in Exosome-containing
Pellets from Postmortem Human Prefrontal Cortex
To confirm the presence of exosomes in our pellet-preparations
from postmortem human frozen BA9 cortices, we examined the
morphology and antigenicity of the pellet content (Figure 1). On
electron microscopy, membrane-bound vesicles with diameters of
70–90 nm were immunoreactive for antigens commonly found in
exosomes, CD63 and GAPDH (Figure 1A and B). Next, we
evaluated the efficiency of our exosomal extractions from brain
tissue. Western blot analysis revealed the presence of flotillin-2,
protein commonly associated with exosomal membrane [35], in
both BA9 pellets and in exosomes-containing pellets from the
medium of cultured H4 cells (Figure 1C). The exosomal extraction
procedures depleted flotillin-2 from the supernatants (Figure 1C).
Table 2. Cont.
miRNA
z-score:
C
z-score:
BD
z-score:
SZ q-value(%)local FDR(%)
hsa-miR-212 20.61587 0.689795 20.05545 32.4408284 72.13105619
hsa-miR-26a 0.832095 -0.49388 20.25366 32.4408284 72.20091674
hsa-miR-383 20.45492 0.701135 20.18466 32.4408284 72.32614427
hsa-miR-422a 20.26395 0.806814 20.40714 32.4408284 72.3764922
hsa-miR-518c* 0.001353 0.564767 20.42459 41.3047974 72.53390646
hsa-miR-196b 20.67575 0.967093 20.2185 41.3047974 72.53717424
hsa-miR-150 0.050418 0.574385 20.4686 41.3047974 72.67544996
hsa-miR-302b* 0.246155 20.65687 0.30804 41.3047974 72.68497047
hsa-miR-134 0.023544 0.583001 20.45491 41.3047974 72.76553336
hsa-miR-9* 0.6188 20.93082 0.23401 41.3047974 72.77217111
hsa-miR-453 20.74878 0.408178 0.25545 41.3047974 72.87972425
hsa-miR-34a 20.5806520.27546 0.64208 41.3047974 72.96315149
hsa-miR-199a 20.04344 0.698393 20.49121 41.3047974 73.19135993
hsa-miR-526c 0.000846 0.548959 20.41235 41.3047974 73.26518389
hsa-miR-515-3p 20.73256 0.530075 0.15187 41.3047974 73.34759333
hsa-miR-215 20.03675 0.717886 20.51085 41.3047974 73.34812817
hsa-miR-181c 0.87805 20.73324 20.1086 41.3047974 73.58552846
hsa-miR-302c* 0.01393 0.540437 20.41577 41.3047974 73.63892656
hsa-miR-211 20.0302 0.714761 20.51342 41.3047974 73.73914691
hsa-miR-515-5p 0.051513 0.532635 20.43811 41.3047974 73.75924315
hsa-miR-520g 20.9506920.92546 1.40711 41.3047974 74.09075907
hsa-miR-142-5p 20.0799 0.677113 20.44791 41.3047974 74.12613458
hsa-miR-524* 20.00157 0.565716 20.42311 41.3047974 74.15676194
hsa-miR-324-5p 20.21206 0.663358 20.33847 41.3047974 74.23525626
hsa-miR-432* 20.13292 0.678476 20.40916 41.3047974 74.28848132
hsa-miR-518f* 20.03101 0.5454 20.38579 41.3047974 74.30610926
hsa-miR-346 0.224671 0.480879 20.52916 41.3047974 74.36735065
hsa-miR-216 20.45903 0.7177 20.194 41.3047974 74.44567177
hsa-miR-361 0.03535 0.671744 20.53032 41.3047974 74.55343752
hsa-miR-98 20.60393 0.234364 0.27717 41.3047974 74.60460599
hsa-miR-484 0.209461 0.738378 20.71088 41.3047974 74.64404077
hsa-miR-189 20.8039220.68433 1.11619 41.3047974 75.05309477
hsa-miR-126* 0.027436 0.621051 20.48637 41.3047974 75.09259849
hsa-miR-545 0.351442 0.506327 20.64333 41.3047974 75.16836638
hsa-miR-302a 20.0864 0.685513 20.44934 41.3047974 75.20719598
hsa-miR-432 20.81081 0.255479 0.4165 41.3047974 75.25585407
hsa-miR-224 20.6587320.04749 0.52966 41.3047974 75.292015
hsa-let-7i 20.5441520.16195 0.52957 41.3047974 75.71872619
hsa-miR-137 0.070381 0.650415 20.5406 41.3047974 75.76579176
hsa-miR-369-5p 0.749466 20.27253 20.3577 41.3047974 75.83285292
hsa-miR-526a 20.04561 0.52662 20.36076 43.4773989 76.60067761
hsa-miR-181b 0.487456 0.434359 20.69136 43.4773989 76.6991424
hsa-miR-365 20.08579 0.600065 20.38571 43.4773989 76.70911636
hsa-miR-512-5p 0.584274 20.53636 20.03594 43.4773989 76.84890105
hsa-miR-493-5p 20.3950220.55077 0.70934 43.4773989 77.04222504
hsa-miR-200a* 20.4127720.31389 0.545 43.4773989 77.05673199
hsa-miR-509 0.610327 20.27544 20.25117 43.4773989 77.06179362
hsa-miR-187 20.5308320.10011 0.4732 43.4773989 77.28591448
hsa-miR-214 20.55444 0.28481 0.20223 43.4773989 77.6270228
Table 2. Cont.
miRNA
z-score:
C
z-score:
BD
z-score:
SZ q-value(%) local FDR(%)
hsa-miR-193b 20.5695 20.27523 0.63355 44.7455322 77.84340704
hsa-miR-18b 0.158782 20.67872 0.38996 44.7455322 78.06910367
hsa-miR-27a 20.6742520.14205 0.61222 44.7455322 78.15702062
The list of 198 miRNAs were narrowed from 312 microRNA using a linear
regression model and subsequently ranked by z-score test statistics. Local FDR
evaluates false discoveries by assigning samples to random groups to test for
statistical significance by chance. The relevance of FDR is determined using q-
values, an analog of the p-value. The 21 top-ranked miRNAs have a q-value
equal to 0%, meaning that it is highly unlikely for this miRNAs to be expressed
differentially by chance among the three groups examined.
SZ= schizophrenia; BD= bipolar disorder; C = controls.
doi:10.1371/journal.pone.0048814.t002
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Table 3. SAM test of Luminex miRNA expression data for BD
and C only.
miRNA q-value(%) local FDR(%)
hsa-miR-219 0 27.05850719
hsa-miR-380-3p 0 28.5520989
hsa-miR-499 0 29.39061044
hsa-miR-497 0 29.86048144
hsa-miR-149 0 30.16935542
hsa-miR-501 0 32.7806583
hsa-miR-29c 0 34.68749497
hsa-miR-30e-3p 12.10826211 36.00723604
hsa-miR-504 12.10826211 37.42550117
hsa-miR-148a 12.10826211 39.79413767
hsa-miR-520a 12.10826211 41.10693353
hsa-miR-526b* 12.10826211 43.98048662
hsa-miR-15b 17.20647773 47.26654182
hsa-miR-342 17.20647773 47.55108918
hsa-miR-29b 17.20647773 49.13804596
hsa-miR-409-5p 17.20647773 50.09111912
hsa-miR-516-5p 17.20647773 50.61439857
hsa-miR-520d* 17.20647773 50.79672442
hsa-miR-500 17.20647773 50.82589406
hsa-miR-368 18.95206243 53.22108834
hsa-miR-30e-5p 18.95206243 54.66652218
hsa-miR-181c 18.95206243 55.4595906
hsa-miR-26b 18.95206243 55.51339027
hsa-miR-511 22.70299145 58.90676274
hsa-miR-527 27.24358974 63.91589056
hsa-miR-483 27.24358974 64.697843
hsa-miR-544 27.24358974 65.0689104
hsa-miR-518a-2* 27.24358974 65.91311804
hsa-miR-370 30.06189213 67.72976336
hsa-miR-100 69.07664285 70.77603166
hsa-miR-498 69.07664285 71.22258291
hsa-miR-9* 71.07023411 74.68821123
hsa-miR-125a 71.07023411 76.54730008
hsa-miR-502 72.64957265 78.54613247
hsa-miR-26a 75.17482517 84.87201631
hsa-miR-181d 77.26224393 94.90250066
hsa-miR-510 77.26224393 95.66638517
hsa-miR-512-5p 78.16485434 100
hsa-miR-299-3p 78.16485434 100
hsa-miR-142-3p 78.16485434 100
hsa-miR-148b 82.00595701 100
hsa-miR-376a 82.00595701 100
hsa-miR-302a* 82.00595701 100
hsa-miR-503 82.00595701 100
hsa-miR-202* 82.00595701 100
hsa-miR-376b 82.00595701 100
hsa-miR-200a 84.15841584 100
hsa-miR-542-3p 84.15841584 100
Table 3. Cont.
miRNA q-value(%) local FDR(%)
hsa-miR-520e 84.15841584 100
hsa-miR-516-3p 84.15841584 100
hsa-miR-302b* 84.54907162 100
The results show 7 miRNAs with q-values equal to 0%.
doi:10.1371/journal.pone.0048814.t003
Figure 1. Characterization of exosome-containing pellets from
human brain tissue. Electron microscopy of exosomal extractions
from BA9 cortices demonstrates the presence of microvesicles (,70–
100 nm in diameter). Upon immuno-gold labeling procedure with
antibodies against CD63 (A; additional negative staining highlights
membrane of the vesicle) and GAPDH (B), the microvesicles reveal the
presence of exosome-associated antigens. Bars indicate 100 nm.
Comparison of exosomal extraction procedure products from BA9
cortices and H4 cell-culture reveals similar outcomes in Western blot.
Supernatant of BA9 exosome-containing pellets (lane 1), supernatant of
H4 exosome-containing pellets (lane 2), BA9 exosome-containing
pellets reconstituted in PBS (lane 3), and of H4 exosome-containing
pellets reconstituted in PBS (lane 4), show robust presence of exosomal
marker flotillin-2 in the pellets, but not in the supernatants (C).
doi:10.1371/journal.pone.0048814.g001
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Luminex miRNA Expression Analysis in Exosome-
containing Pellets from SZ and BD Patients Suggest
Differential Expression of a Subset of miRNAs in
Comparison to Controls
Luminex miRNA expression data in exosome-containing pellets
from prefrontal (BA9) gray matter of 8 SZ patients (SZ 1–8), 6 BD
patients (BD 1–6), and 6 controls (C 1–6) (Table 1) were submitted
to Student’s t-test. These data reveal several significantly
differentially expressed miRNAs in either BD or SZ, or both in
comparison to controls. Bonferroni Step-down Holm Correction
was then applied to correct for multiple comparisons [39]. This
correction resulted in the absence of significantly differentially
expressed miRNAs in BD samples, while the expression of only
three miRNAs (miR- 31, -33, and -96) was significantly enhanced
in SZ samples in comparison to controls and to BD (Table S1). In
an alternative statistical approach towards identification of
miRNAs differentially expressed in the three groups examined,
we submitted raw Luminex miRNA expression data to Significance
Analysis of Microarrays (SAM) program [36],[37] (Table 2). SAM
ranked the expressions of examined miRNA expression using z-
scores (Table 2). For the 21 top-ranked miRNAs, Prediction
Analysis of Microarrays (PAM) [38]– derived q-value was 0%
(Figure 2). We next examined how the expression of these 21 top-
ranked miRNAs might influence the clustering of our samples.
Surprisingly, the dendrogram from the clustering analysis [38]
(Figure 3) suggests that the expression the 21 top-ranked miRNAs
segregated SZ samples from BD samples and controls, leaving BD
samples and controls undifferentiated from one another. In order
to remove the influence of SZ group on the ranking system, the
SAM program was run again for BD and control groups only
(Table 3) and yielded 7 miRNAs with q- value of 0% (Table 3).
This group of miRNAs, however, had a rather limited ability to
segregate BD samples from controls (cluster dendrogram not
shown). These results prompted us to submit the entire Luminex
data to a PAM-derived misclassification rate analysis to determine
if the miRNA expression values of each sample in a group have a
reliable predictive power, i.e. if they can serve as biomarkers for a
given group [42]–[38]. The misclassification rate was 0 for the SZ
group (Figure 4), indicating that: a) the examined miRNA
expressions were tightly grouped in SZ as previously indicated
by the cluster dendrogram (see Figure 3); and b) the expression
values of a very small number of miRNAs can assign an SZ sample
to its correct group. The control samples had most variable
miRNA expression levels associated with high misclassification
rate regardless of how many miRNAs were evaluated (Figure 4).
Finally, Figure 4 shows that the misclassification rate for BD
samples is dependent on the number of miRNAs evaluated: if
,13–16 miRNAs are taken into account, BD samples separate
well from controls and reach zero misclassification rate that is
characteristic of SZ samples (Figure 4).
Covariate Analysis: the Effect of Medications on SAM
Results
The clinical information accompanying our samples failed to
provide sufficient data to control for tobacco, alcohol or
recreational drug consumption (Table S4), while the information
of prescribed medications (Table 4) was well defined. The cases
were marked if the patients took at least one medication from the
seven drug classes constructed on the basis of the common
mechanism(s) underlying drug effect (A-G; Table 5). Since a
standard error is used to generate a covariate effect, only drug
classes with at least three case-subjects taking a drug and three
case-subjects not taking a drug could be evaluated as covariates.
Thus, only drug classes A (antipsychotics used in SZ only), B
(neurotransmitter receptor-site binders used in both BD and SZ),
and C (sedatives, hypnotics, anticonvulsants and analgesics used in
both BD and SZ) could be controlled for.
Figure 2. Median and 90th percentile of False Discovery Rates (FDR) in order left-to-right of threshold value and number of
statistically significant results for all three groups (C, BD, and SZ). The Y-axis is an estimate of the percentage of false positives. High-ranked
miRNA (at the left) have a low rate of false positives, while lower-ranked miRNA (moving toward the right) have higher rates of false positives.
doi:10.1371/journal.pone.0048814.g002
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In a simple format of covariate adjustment [46] the effects of
multiple independent variables are added together in a linear
regression model. To guard against Type I errors, we designed a
model to adjust for covariates using the SAM program. SAM was
rerun to compare case subjects taking a specific drug class
medication against case subjects not taking it, and a list of
covariate effects for drug classes A–C was derived for top-ranked
miRNA in the study (Table 6). Those effects were then subtracted
from the original z-scores (Tables 2 and 3) and p-values were
added to demonstrate the effects of the covariate on significance
(Tables 7 and 8).
When adjusted for drug class A (antipsychotics used in SZ only),
the significance of results for miRNAs 31, 33, 96, 30e-5p, and
199a* was preserved, while miRNAs 15b, 455, 32, and 20b
acquire significance (Table 7, see also Table 2). After the
adjustment for B (neurotransmitters receptor-site binders) and C
(sedatives, hypnotics, anticonvulsants and analgesics) drug classes
in SZ subjects, the significance for miRNAs 31, 33, 96, 30e-5p,
Figure 3. Hierarchical clustering analysis of top 21 ranked miRNAs from FDR analysis. Correlation coefficient (cc) was generated to assess
the relationship between the expression values of each sample and the rest of the samples (see Methods). The coefficient is 1 if their expression
profiles are highly similar and 0 if their expression profiles are highly divergent. The clustering graph is built so that the samples with similar
expression patterns are clustered at the bottom while more differential patterns are at the top of the graph.
doi:10.1371/journal.pone.0048814.g003
Figure 4. Misclassification rate analysis. (A) Controls (red) have the most variable miRNA expression. The expression data have less variability in
BD (green) and the least in SZ (blue; misclassification rate = 0), resulting in stronger predictive power within their respective clinical groups.
doi:10.1371/journal.pone.0048814.g004
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and 199a* was still preserved while miR-455 (again) acquired
significance together with miR-323 (Table 7, see also Table 2). In
BD subjects, the consideration of combined effects of B and C
drug classes heightened the significance of the results for miRNAs
219 and 29c while miRNA 30e-3p and 526b* acquired
significance (Table 8, see also Table 3). Importantly, Wilcoxon
test also indicated the expression of miRNAs 219 and 526b to be
significantly different in BD cases in comparison to controls, but
failed to discover miRNA 29c (Table S3; see Discussion).
Finally, while effects related to gender were not relevant to this
study due to a male dominated cohort, we did consider the ages of
our cases (Table 1). Although the SZ group of cases is on average
older than BD and control groups, no significant difference in age
between groups exists (Table S5).
qPCR Analysis Confirms Differential Expression of miR-
497 in SZ, and miR-29c in BD Samples in Comparison to
Controls
To verify microarray data for miRNAs that may be differen-
tially expressed in our three analyzed groups, controls, BD, and
SZ, we performed a series of qPCR experiments. The primers for
the following miRNAs worked in reactions with cDNA derived
from each of our samples available for analysis: miR-31, -15b, -
29c, -497, -219, and -149. These miRNAs were among the highest
ranked according to the likelihood to be differentially expressed in
both SZ and BD (miR-31, -15b, -29c, and -497; Table 2), or just
BD (miR-219 and -149; Table 3). To further test the reproduc-
ibility of our data we used additional BD and additional control
cases that became available through brain banks and BMC
autopsy service (Table 1): SZ 1–6 (same as in Luminex experiment),
BD 5–9 (three new samples), and C 6–13 (seven new samples). As
shown in Table 9 and Figure 5, qPCR analyses confirmed miR-
29c to be significantly differentially expressed (2.77 fold increased)
in the examined BD samples, and miR-497 in SZ samples (2.35
fold increased) in comparison to controls.
Discussion
While genetic component has been extensively researched in
BD and SZ patients, the biological markers for these diseases have
proven remarkably elusive. The putative susceptibility genes in
both BD and SZ regulate cell-signaling [47–48]. This study
analyzed the expression of miRNAs found in exosomes (Figure 1A
and B), signaling vesicles capable of cell-to-cell transfer of
miRNAs, in the prefrontal cortices of patients diagnosed with
either BD or SZ and of individuals with no mental illnesses.
Standard statistical analysis (Student’s t-test with Bonferroni Step
Down/Holm correction) of the results of Luminex oligonucleotide-
based screen for the expression of 312 miRNAs revealed only
three miRNAs differentially expressed in SZ in comparison to BD
and control samples (Table S1). While these three miRNAs (miR-
31, -33, and -96) were also most highly ranked in a z-score based
SAM, an additional 18 miRNAs were suggested to have truly
differential expression (Table 2). Accordingly, the expression
values of about 21 miRNAs were not false discoveries in a three-
way comparison (Figure 2). These 21 miRNAs distinguished SZ
but not BD samples from controls relatively well (Figure 3). Upon
elimination of the distinctive influence of SZ samples in the three-
way comparison (Table 2), the short list of most differentially
expressed miRNA in BD compared to controls (Table 3) still
featured several of the original top 21-ranked miRNAs. The
covariate adjustment for the medications used by some of the
subject cases (Tables 4 and 5), had nominal effects on significance
of differential miRNA expression in the SZ group, while in the BD
group the difference in the expression of miR-30e-3p, -219 and -
29c attained heightened significance (Tables 6–8). To verify the
microarray data, we performed qPCR analysis of the selected
miRNAs in a partially new set of samples. Two miRNAs were
Table 4. Medications (grouped in classes A-G) prescribed to subject cases for psychiatric and neurological symptoms.
Case Medications prescribed for psychiatric and neurological symptoms, daily mg A B C D E F G
SZ1 Levomepromazine 100, Haloperidol 10, Diazepam 5 X X
SZ2 Amisulpride 200, Quetiapine 200, Clonazepam 0.5, Oxcarbazepine 300 X X
SZ3 Haloperidol 5, Olanzapine 10, Lorazepam 1, Clomethiazole 192, Imipramine 50 X X X
SZ4 Lormetazepam 1, Olanzapine 10, Lorazepam 1, Clomethiazole 192 X X
SZ5 Olanzapine 15 X
SZ6 Phenitoine 100 X
SZ7 Clozapine 400, Trazadone 50, Haloperidol 5, Lorazepam 1 X X X X
SZ8 None
BD1 Lithium 400, Methylphenidate 20, Diazepam 10, Oxazepam 20 X X X
BD2 Lithium 400, Quetiapine 25, Midazolam (amount?) X X X
BD3 Risperidone 1.5, Gabapentin 600, Nefazodone 600, Topiramate 75, Ziprasidone 20 X X X
BD4 Valproic acid 1500, Paroxetine 20, Clonazepam 4, Olanzapine 10 X X X
BD5 Lithium (amount?) X
BD6 Valproic acid 1000, Quetiapine 125 X X
BD7 Moclobemide 300 X
BD8 Dexamphetamine sulphate 5 X
BD9 Tranylcypromine 60 X
C1–C13 None
SZ = schizophrenia; BD= bipolar disorder; C = controls.
doi:10.1371/journal.pone.0048814.t004
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confirmed to have significantly altered expression: in comparison
to controls, the expression of miR-497 and miR-29c were
significantly higher in SZ samples and BD samples, respectively
(Table 9).
Our study has several novel and important findings. While
exosomal content has been intensively studied in human diseases
ever since the report of Valadi et al. in 2007 [30], we
demonstrated here for the first time that exosomal miRNAs could
Table 5. Classes (A–G) encompassing the medications in Table 4.
Class Description of medication class
Prescribed medication
from the class Effects
A Antipsychotics specifically for SZ Levomepromazine Phenothiazine Group; dopamine, adrenalin, histamine,
acetylcholine and serotonin antagonist; antipsychotic
effects
A Antipsychotics specifically for SZ Haloperidol dopamine antagonist; effects similar to Phenothiazine
group; antipsychotic effects
B Neurotransmitter receptor- site binders used
in BD and SZ
Olanzapine dopamine, serotonin, adrenergic antagonist with
antihistaminic effect; antipsychotic properties
B Neurotransmitter receptor- site binders used
in BD and SZ
Clozapine dopamine, serotonin, adrenergic antagonist with
antihistaminic effect; antipsychotic properties
B Neurotransmitter receptor- site binders used
in BD and SZ
Quetiapine dopamine, serotonin, adrenergic antagonist with
antihistaminic effect; antipsychotic properties
B Neurotransmitter receptor- site binders used
in BD and SZ
Amisulpride dopamine and serotonin antagonist; antipsychotic
properties
B Neurotransmitter receptor- site binders used
in BD and SZ
Risperidone dopamine, serotonin, adrenergic antagonist with
antihistaminic effect; antipsychotic properties
B Neurotransmitter receptor- site binders used
in BD and SZ
Ziprasidone dopamine, serotonin, adrenergic antagonist with
antihistaminic effect; antipsychotic properties
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Diazepam Benzodiazipines, i.e. GABA agonists; sedative, hypnotic,
with anticonvulsant effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Clonazepam Benzodiazipines, i.e. GABA agonists; sedative, hypnotic,
with anticonvulsant effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Lorazepam Benzodiazipines, i.e. GABA agonists; sedative, hypnotic,
with anticonvulsant effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Oxazepam Benzodiazipines, i.e. GABA agonists; sedative, hypnotic,
with anticonvulsant effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Midazolam Benzodiazipines, i.e. GABA agonists; sedative, hypnotic,
with anticonvulsant effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Clomethiazole GABA agonist; sedative, hypnotic, with anticonvulsant
effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Oxcarbazepin ion, mostly sodium, channel stabilizer; anticonvulsant
and mood stabilizing effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Phenitoin sodium channel stabilizer, anticonvulsant effect
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Gabapentin GABA agonist; anticonvulsant and analgesic effects
C Sedatives, hypnotics, anticonvulsants and analgesics
in BD and SZ
Topiramate mechanism unclear; anticonvulsant effect
D Antipsychotics specifically for BD Valproic acid GABA effects enhancer; anticonvulsant and mood-
stabilizing effects
D Antipsychotics specifically for BD Lithium mechanism unclear; mood-stabilizing effects
E Psycho-stimulants used in BD Moclobemide monoamine oxidase inhibitors; antidepressant effects
E Psycho-stimulants used in BD Tranylcypromine monoamine oxidase inhibitors; antidepressant effects
E Psycho-stimulants used in BD Methylphenidate dopamine enhancer, psychostimulant
E Psycho-stimulants used in BD Dexamphetamine psychostimulant
F Serotonin and adrenergic antagonists for BD Nefazodone serotonin and adrenergic antagonist; antidepressant
effects
F Serotonin and adrenergic antagonists for BD Paroxetine serotonin re-uptake inhibitor; antidepressant and
anxiolytic effects
G Serotonin antagonist for SZ Trazodone serotonin antagonist and reuptake inhibitor,
antidepressant, anxiolytic, and sedative effects
SZ = schizophrenia; BD= bipolar disorder.
doi:10.1371/journal.pone.0048814.t005
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be obtained from frozen postmortem brain tissue. On electron
microscopy our PFC- derived exosome-containing pellets showed
membrane bound vesicles within the range of the reported size of
exosomes [49] (Figure 1A and B). In addition to the identification
by size, shape, and miRNA content (intracellular micro-vesicles of
similar size, e.g. lysosomes, do not contain miRNAs), we
demonstrated a robust signal for CD63 and GAPDH in the
micro-vesicles extracted from the human PFC (Figure 1A and B).
According to Mathivanan and Simpson (2009) [50] exosomes
from different sources have varying sets of protein markers on their
surface, with CD63 being the second most, and GAPDH being the
fourth most commonly reported exosomal antigen. Finally, our
exosome-containing pellets were enriched with exosomal marker
flotillin-2 [35] on Western blots, similar to the pellets from the
medium of cultured cells (Figure 1C). Having insight into the
cortical exosomal miRNA content may be of particular impor-
tance because exosomes are released into the CSF, and thus
accessible for evaluation in living patients [51]. A recent study
identified a substantial number of miRNAs exclusively or
predominantly expressed in CSF [52]. Comparing the data from
brain tissue with CSF will indeed require clinical investigation
since postmortem brain depositories do not currently have
sufficient number of samples and/or amount of CSF from
neuropsychiatric patients. So far, the search for specifically altered
miRNA expression in peripheral blood mononuclear cells
(PBMCs) in SZ yielded diverse results [53], [54]. Three miRNAs
were found to be differentially expressed in PBMCs as well as in
PFC (BA46) of SZ patients [53–55].
The second novel and important feature of our investigation lies
in the fact that our statistical analyses pointed to both differences
and similarities between the miRNA expression changes in SZ and
BD samples in comparison to control samples. The SAM top 21-
ranked miRNAs (Table 2, Figure 2) had the ability to separate SZ
samples, but not BD samples from the controls (Figure 3). This
finding is directly connected to the suggested inherent differences
in the variability of miRNA expression values in control samples in
the three analyzed groups of samples, illustrated by the misclas-
sification error rate analysis (Figure 4). The high variability of
miRNA expression values in control samples represents perhaps a
defining feature - the agility of the cortical transcriptional
regulation in the absence of mental disease.
Initial statistical analysis revealed three miRNAs (miR-31, -33,
and -96) differentially regulated in SZ samples (Table S1). Of those
three, miR-33 was previously reported among misexpressed
miRNAs in PFCs of both SZ and BD individuals [10]. Since we
performed qPCR for additional miRNAs that were likely to be
differentially expressed in SZ and BD samples according to SAM
(Tables 2 and 3), we found significantly increased miR-497
expression in exosome-containing pellets from PFCs of SZ patients
(Table 9). Perkins et al. (2007) [11] reported 16 miRNAs to be
differentially expressed in PFCs of SZ subjects, one being miR-
195. Both miR-195 and -497 belong to the well-studied miR-15/
107 gene family. miR-15/107 miRNAs share most of their targets
and are implicated in the pathogenesis of neoplasms, neurode-
generative diseases and heart disease [56]. Importantly, the up-
regulation of these miRNAs expected to affect cortical gene
expressions, has been reported in SZ [57]. Interestingly, miR-497
was also found to promote ischemic neuronal death by negatively
regulating anti-apoptotic proteins, bcl-2 and bcl-w [58]. Three
more miRNAs from our SAM top 21-ranked miRNAs were on the
list of significantly down-regulated miRNAs in SZ by Perkins and
colleagues [11]: miR-92, -20b, and -30e. miR-92 and -20b belong
to miR-17-92 cluster known to be a potent oncogene [59].
Potentially pertinent for SZ pathobiology, miR-92 has also been
suggested to developmentally regulate neuronal K(+)Cl(2) co-
transporter 2 (KCC2) that modulates effects of GABA [60].
Finally, miR-30e may regulate neuronal death as down-regulation
of miR-30e expression promoted neuronal survival in long-lived
calorie-restricted mice [61]. However, we were not able to validate
differential expression of miRNA-30e in the exosome-containing
samples of PFCs in SZ (data not shown). We found miR-29c to be
significantly increased in the exosome-enriched preparations from
PFC of individuals diagnosed with BD in comparison to controls
according to SAM and qPCR analysis. Interestingly, the
expression of miR-29c was not significantly different in BD cases
compared to controls according to Wilcoxon test applied to our
Luminex data (p-value 0.0649; Table S3). The fact that miR-29c
was significantly differentially expressed in SAM (Tables 2 and 3),
further confirmed by qPCR analysis in BD vs. controls (Table 9),
suggests that FDR testing through the use of SAM might be a
superior strategy for discovery of true positives.
Like miR-497, the miRNA confirmed to be up-regulated in SZ
samples, miR-29c was among the top-ranked in both SAM
analyses (Table 2 and 3). In other words, both of these miRNAs
were considered highly differentially regulated in both diseases
according to SAM. Moreover, miR-29c was also reported by
Table 6. Covariate effects of medications on highly-ranked
miRNAs in SAM (top-21 in Table 2 and top-12 in Table 3).
miRNA Class A Class B Class C
hsa-miR-31 20.5474735 0.0027362
hsa-miR-33 0.6342707 20.3112329 0.9637398
hsa-miR-96 0.040926 0.5554684
hsa-miR-28 1.1396825 1.0107414
hsa-miR-30e-5p 0.3379079
hsa-miR-199a* 20.8762626
hsa-miR-501 0.0812317 20.167766 20.6013733
hsa-miR-504 0.2946595 20.1356475 20.3858902
hsa-miR-15b 20.1307195
hsa-miR-29c 20.1678 0.3820155 0.1279756
hsa-miR-455 20.2162923 20.2365768
hsa-miR-380-3p 20.1295169 20.2513642 20.2837673
hsa-miR-323 0.0956179 20.3292096
hsa-miR-527 0.3199353 20.3980191 20.4156484
hsa-miR-93 0.8926459 0.8342627 1.4247242
hsa-miR-32 20.3081563
hsa-miR-20b 20.3025591
hsa-miR-516-5p 0.1006308 20.2462411 20.4384718
hsa-miR-92 1.5916982 1.9080176
hsa-miR-30a-3p 0.2072069
hsa-miR-497 0.1045716 20.2486034 0.036478
hsa-miR-219 0.3630727 20.2988121
hsa-miR-499 20.0609767 20.3046793 20.2561058
hsa-miR-149 0.654253 20.2538624 0.04254
hsa-miR-30e-3p 0.4068861 20.0672197 0.11598
hsa-miR-148a
hsa-miR-520a 20.0963095 21.5626633
hsa-miR-526b* 0.3595811 0.594503
doi:10.1371/journal.pone.0048814.t006
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Perkins et al. to be differentially expressed miRNAs in PFC of SZ
patients [11]. Interestingly, miR-29 together with miR-31, the top-
ranked differentially expressed miRNA by SAM but not by qPCR
(Table S1, Table 8), was proposed to regulate several cell-adhesion
machinery components that are affected in the pathogenesis of
many diseases [62]. The up-regulation of miR-29c in the cortical
exosomes of BD patients is particularly intriguing because miR-
29c is induced by canonical Wnt signaling [63] that is antagonized
by GSK-3, a know substrate of inhibition by lithium, a first line of
therapy for BD [64].
The interpretation of our findings has the following limitations.
First, the relationship between exosomal and cellular miRNAs is
not understood: is the exosomal miRNA aberration a part of
pathogenesis, or a corrective attempt? Second, age-associated
common brain pathology, may complicate the interpretation of
our results, although vascular and early Alzheimer’s disease-
associated pathologies were relatively evenly distributed in our
samples (Table 1). Third, we were limited by a finite number of the
samples available that fulfilled the RNA quality standards.
However, the statistical methods we applied were developed
specifically as a ‘‘non-parametric’’ test for miRNA expression
studies. This test has a built-in mechanism for evaluating small
sample sizes, and makes use of a ‘‘positive constant’’ standard error
value as one of its formulaic variables. This ensures that miRNAs
with small values are not elevated high in the rankings simply
because they have a small standard error. By comparison t-tests
often assign strong significance to miRNAs with small expression
levels due to their small standard errors. The PAM and SAM
programs we used are therefore optimal in dealing with irregular
data with small sample size such as ours.
Fourth, our microarray examined the expression of 312
miRNA, while hundreds more are known to exist and thus may
be important for the pathobiology of SZ and BD. Finally, due to
the variable efficiency of the primers in our cDNA samples, we
could carry qPCRs for only six miRNAs (Table 8, 9) featured
among our top-ranked in SAM analyses (Tables 2 and 3).
Table 8. Top-ranked miRNAs from Table 3, adjusted for covariate effects of medications (classes B, C, and B+C).
miRNA
BD score
(z-score from
SAM) p-value
Class B covariate
adjust p-value
Class C covariate
adjust p-value
Classes B+C
covariate adjust p-value
hsa-miR-219 22.8237 0.0074 22.8237 0.0074 23.1225 0.0030 23.1225 0.0030
hsa-miR-380-3p 22.2933 0.0287 22.0419 0.0496 22.0095 0.0529 21.7581 0.0850
hsa-miR-499 22.2226 0.0337 21.9179 0.0634 21.9665 0.0576 21.6618 0.1002
hsa-miR-497 22.1947 0.0358 21.9460 0.0600 22.2311 0.0331 21.9825 0.0558
hsa-miR-149 22.1785 0.0371 21.924 0.0625 22.2211 0.0338 21.9672 0.0576
hsa-miR-501 22.0751 0.0463 21.9073 0.0647 21.4737 0.1346 21.3059 0.1700
hsa-miR-29c 22.0161 0.0522 22.3981 0.0224 22.1440 0.0400 22.5260 0.0164
hsa-miR-30e-3p 21.9787 0.0563 22.0274 0.0444 22.0947 21.9115 0.0641 0.0510
hsa-miR-504 21.9404 0.0607 21.4189 0.1191 21.5545 21.8048 0.0782 0.1457
hsa-miR-148a 21.8790 0.0682 21.8790 0.0682 21.8790 21.8790 0.0682 0.0682
hsa-miR-520a 21.8457 0.0726 20.2830 0.0726 21.8457 20.2830 0.3832 0.3832
hsa-miR-526b* 21.7745 0.0826 22.3691 0.0826 21.7745 22.3691 0.0241 0.0241
The consideration of combined effects of B and C drug classes heightened the significance of the results for miRNAs 219 and 29c (bold; see Table 3), while miRNA 30e-
3p and 526b* (bold) acquired significance.
BD= bipolar disorder.
doi:10.1371/journal.pone.0048814.t008
Figure 5. In comparison to controls, the expression of miR-29c and miR-497 is significantly increased in BD and SZ samples,
respectively. Average exosomal RNA extracted from BA9 cortices of BD samples show a 2.77 fold increase of miR-29c in comparison to controls (A).
SZ samples reveal 2.35 fold increase of miR-497 when compared to controls (B). Error bars indicate S.E.M.
doi:10.1371/journal.pone.0048814.g005
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Nevertheless, the results of qPCR validation are remarkable
considering that we examined different samples from the ones
analyzed in the microarray, in particular controls - most likely to
exhibit highly variable miRNA expressions (Figure 4). Interesting-
ly, our qPCR analysis did not validate SZ-associated highly
significant up-regulation of miR-31 by Luminex assay (Table 2,
Table S1). Considering, however, that Gardiner et al. (2012) [54]
confirmed miR-31 down-regulation in PBMCs of SZ patients,
miR-31 dysregulation in SZ cannot be ruled-out. Our search for
exosome-derived biomarkers yielded two candidates, miR-497 and
miR-29c, in the PFC of SZ and BD patients respectively,
potentially offering a novel insight into the pathogenesis of these
diseases. In addition, rapid development of exosome nanotech-
nology [65] adds the promise of alternative therapeutics delivery
[66–67] to the emerging diagnostic potential of brain-derived
exosomes in neuropsychiatric diseases.
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Supporting Information
Figure S1 RNA quality control. Representative RNA (sample
C13, RIN=7.0; the sample closest to the average (6.96) and
median (6.85) value for the set) yields two strong bands at 40 s and
45 s representing the 18 S and 28 S ribosomal RNA (A). The
electropherogram shows a marker peak and the two ribosomal
peaks corresponding to 18 S and 28 S subunits. RIN value on a
scale of 1–10 is computed based on the presence of correct
ribosomal peaks, the ratio between those peaks, and the extent of
RNA fragmentation (B). Relationship between RIN and mRNA
and miRNA profiles (C): Next to the ladder (left), total and small
RNA profiles of three degradation stages of a single RNA sample
are shown (RIN 8.4= not degraded, RIN 3.1= partially
degraded, RIN 2.5= severely degraded). Note that both mRNA
(RT PCR, middle) and miRNA (Luminex, right) profiles obtained
from a sample with RIN 3.1 (low in comparison to the average
RIN of 6.96 in this study) are still relatively similar to the profile
obtained from a sample with high (8.4) RIN.
(TIF)
Figure S2 RNase treatment effect on total RNA profile.
Agilent RNA 6000 Pico chips have the ability to resolve RNAs in the
size range of 25 nt to 6000 nt (top row). Agilent Small RNA chips
have superior resolving power for RNAs in the range of 4 nt to
150 nt only (bottom row). Electropherogram from Pico chip shows
that in addition to miRNAs, our exosome preparations also
contain higher molecular weight cellular RNAs of sizes up to
4000 nt. These higher molecular weight species cannot be seen
with the small RNA chips. Digesting exosome preparations with
RNase A or a combination of RNase A and RNase T1 destroys
the higher molecular weight extra-exosomal cellular RNAs and
preserves only the small RNAs contained in the exosome itself.
Note, also, that the fluorescent units scale [FU] on the Y-axis of all
of the electropherograms represents the quantity of RNA. As such,
RNase treated preps contain much less RNA than untreated preps
as the exosomal RNA represents a small portion of the cellular
RNA. Similarly, RNase digestion reduces both the size and
amount of small RNAs present in exosomal preparations.
Exosomal RNA preparations not treated with RNase contain
more and larger RNAs in the 4–150+ nt range than do
preparations treated with RNase A alone or RNases A and T1.
The expected size ranges of miRNAs (,19–28 nt, yellow) and pre-
miRNAs (45–60 nt, blue) are indicated in the small RNA assay
panels (bottom row). RNAs in these size ranges are well
represented in our purified exosomal RNA preparations.
(TIF)
Figure S3 NCode amplification of exosome-derived
RNA. Amplification of miRNAs (which have no poly-A tails)
requires the addition of a 39 Oligo(dT) 24-mer as well as a 59 T7
promoter template, which increases the size of each miRNA by
,40 nt. In this case, the expected size range of amplified miRNAs
is ,60 nt (arrow) as opposed to that of the native ,20 nt species.
Profiles of amplified miRNA upon treatment with RNase A
(green), without RNase (blue), and with RNase A/T1 (red –
optimal for exosome-derived RNA used in Luminex assay) are
similar.
(TIF)
Table S1 Student’s T tests of Luminex miRNA expres-
sion data with corrected p-values.
(DOCX)
Table S2 Quantities of exosome-derived miRNA from
the analyzed cases for Luminex assay, before and after
NCode amplification.
(DOCX)
Table S3 Wilcoxon non-parametric test and fold change
for top BD hits as means for statistical verification.
12 top-ranked miRNAs according to SAM in Table 3, with q-
values lower than 15%, ending with miR-526b* - the last miRNA
Table 9. Student’s t-test comparison of qPCR Delta-CT.
miRNA p-value, BD Significant fold change p-value, SZ Significant fold change
hsa-miR-15b 0.6971 0.7906
hsa-miR-29c 0.0237 2.77 0.501
hsa-miR-31 0.426 0.3699
hsa-miR-149 0.591 0.5011
hsa-miR-219 0.8723 0.4059
hsa-miR-497 0.1969 0.0026 2.35
miR-29c expression is significantly increased in BD samples, and miR-497 in SZ samples.
BD= bipolar disorder; SZ = schizophrenia.
doi:10.1371/journal.pone.0048814.t009
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to have significantly changed expression in BD according to this
test. miRNAs 219, 380–3p, 148a, 520a, and 526b* (p-values in
bold) have significantly changed expression in BD cases in
comparison to controls by this analysis. The expression of miR-
29c is not significantly different in BD cases according to Wilcoxon
test (p-value 0.0649; see Discussion).
(DOCX)
Table S4 Phenotype traits (tobacco, alcohol, and recre-
ational drug use) of analyzed cases.
(DOCX)
Table S5 An ANOVA analysis of differences in age
between C, BD, and SZ groups of cases. No significant
difference in age between the groups exists.
(DOCX)
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